Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture
- 27 Downloads
Systemic heparinization often increases the risk of fatal bleeding from other injured organs in surgical repair of the aorta using extracorporeal circulation in patients with traumatic aortic rupture associated with multisystem injuries. We used an antithrombin agent, argatroban, as an alternative anticoagulant in left heart bypass with the Bio-Medicus centrifugal pump in 7 of 9 recent patients who underwent aortic repair using left heart bypass. All these patients survived without obvious evidence of systemic thromboembolization. Surgical treatments for other organ injuries were carried out in 3 patients concomitantly or immediately after aortic repairs without undue blood loss. Argatroban may have a complementary effect for preventing thrombus formation without aggravating bleeding tendency because of its monotarget specificity to thrombin. We believe intravenous administration (0.5 to 2 μg/kg/min) of argatroban is a safe anticoagulant for left heart bypass in repairs of traumatic aortic rupture associated with multiple organ injuries.
Index wordsArgatroban traumatic aortic rupture left heart bypass Bio-Medicus centrifugal pump
Unable to display preview. Download preview PDF.
- 3.Kawada T, Mieda T, Hoson M, Koyama T, Abe H, Funaki S, et al. Left heart bypass with the Bio-Medicus centrifugal pump: the use of argatroban for preventing platelet loss. Artif Organs Today 1992; 2: 177–84.Google Scholar
- 6.Soots G, Warembourg H Jr, Prat A, Roux JP. Acute traumatic rupture of the thoracic aorta: place of delayed surgical repair. J Cardiovasc Surg 1989; 30: 173–7.Google Scholar
- 8.Dixon CM, Magovern J. Evaluation of the Bio-Pump for long-term cardiac support without heparinization. J Extracorp Technol 1982; 14: 331–6.Google Scholar
- 10.Sugawara H, Kumon K, Tanaka K, Esato Y, Naitou Y, Fujita T. Evaluation of a synthetic thrombin inhibitor MD 805 as anticoagulant after open heart and vascular surgery. Jpn J Thorac Surg 1983; 36: 533–7.Google Scholar
- 11.Fukutake K, Tateyama M, Amano K, Ueda M, Fujimaki M. Clinical pharmacology of argatroban, selective antithrombin agent: comparative study with heparin. Cardioangiology 1991; 29: 190–6.Google Scholar